Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
38.31
+1.08 (+2.90%)
5:27:54 PM EDT: $38.43 +0.12 (+0.31%)
Products, Regulatory, Earnings Announcements

Pfizer Announces Positive Phase 3 Study Results For Xeljanz ® (Tofacitinib) In Ankylosing Spondylitis (As)

Published: 11/06/2020 12:13 GMT
Pfizer Inc (PFE) - Pfizer Announces Positive Phase 3 Study Results for Xeljanz ® (tofacitinib) in Ankylosing Spondylitis (as).
Pfizer Inc - Study Met Its Primary and Key Secondary Endpoint of Assessment in Spondyloarthritis International Society (asas) 20 and 40 Response.
Pfizer Inc - FDA Has Accepted Pfizer's Application for As Indication and Prescription Drug User Fee Act (pdufa) Goal Date is in Q2 2021.
Pfizer Inc - Percentage of Asas40 Response Was Significantly Greater With Tofacitinib (40.6%) Versus Placebo.
Revenue is expected to be $12.9 Billion
Adjusted EPS is expected to be $0.55

Next Quarter Revenue Guidance is expected to be $12.17 Billion
Next Quarter EPS Guidance is expected to be $0.68

More details on our Analysts Page.